Information Provided By: 
Fly News Breaks for December 5, 2019
ACLS
Dec 5, 2019 | 07:46 EDT
DA Davidson analyst Thomas Diffely initiated coverage of Axcelis with a Buy rating and a $30 price target. The analyst has a "multi-year bullish" outlook on the company given its "significant" drivers around the ion implant market and its "strong leverage" around the expected memory recovery cycle. Diffely adds that the recently launched product extensions for Axcelis' Purion platform should increase its presence across multiple end markets and help in its path for re-entry in Japan.
News For ACLS From the Last 2 Days
